Shanghai Jiao Tong University announces the localization of quantum dot liquid biochips

According to the official website of Shanghai Jiao Tong University, on March 25th, a team led by Li Wanwan, a researcher at the School of Materials Science and Engineering and Zhangjiang Institute of Advanced Research at Shanghai Jiao Tong University, along with Zhejiang Oriental Gene Biological Products Co., Ltd., Hangzhou Deep Biotechnology Co., Ltd., and Shanghai Wanzijian Biotechnology Co., Ltd., spent 18 years achieving a complete full chain technological breakthrough from quantum dot fluorescent microspheres, detection analyzers to supporting testing reagents. They jointly developed a quantum dot liquid biochip multi index in vitro detection system and created a quantum dot liquid biochip technology platform with independent intellectual property rights.

It is reported that liquid biochips are suitable for both nucleic acid and protein biomarkers, with high detection flux and sensitivity. They can simultaneously analyze dozens of target substances in single tube samples, significantly improving detection efficiency and revolutionizing clinical laboratory testing. Liquid biochip technology is a new type of detection technology, in which fluorescent coding microspheres are the "core" of multi indicator detection. For example, using fluorescent encoded nanospheres, only a very small amount of serum is needed to perform detection of more than ten indicators, which can significantly reduce detection costs.

It is reported that the quantum dot liquid biochip multi index in vitro detection system has advantages such as small volume, full automation, high flux, small sample size, high accuracy, good repeatability, wide linear range, and low cost. At the same time, based on the detection system, the development of multiple indicator detection reagents for cancer, autoimmune diseases, cardiovascular diseases, infectious diseases and other proteins/nucleic acids has been carried out. At present, the series of detectors and matching detection kits have obtained 15 EU CE certification and China NMPA medical device registration certificates. More series of joint detection reagents are also in the process of application or approval. They have formed the ability to compete with similar high-end technology and equipment abroad, and have been fully implemented and promoted worldwide, breaking the monopoly of major international companies.